TwitterFacebookLinkedIn

Upcoming Webinars

Refresher on Selecting Genetic Testing
for Ovarian Cancer Treatment Decisions

This webinar will include faculty discussing the practicalities of choosing available tumor and germline testing options along with treatment options. Attendees will learn how to how to utilize HRD testing in ovarian cancer treatment decisions.

Thomas C. Krivak, MD
Director, Division of Gynecologic Oncology 
Director, Gynecologic Oncology Research Program
The Western Pennsylvania Hospital
USA

Leigha Senter-Jamieson, MS, CGC
Certified Genetic Counselor
Associate Director of Division of Human Genetics
The Ohio State University
USA

Supported in part by GSK

Recently Recorded

The Evolving Treatment Landscape for The Management of Endometrial Cancer

 IGCS and Eisai welcomes gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies to view the first presentation from the An Evolving Frontier - Understanding Novel Treatment Options for The Management of Advanced Stage or Recurrent Endometrial Cancers Industry Supported Symposium presented at the IGCS 2023 Annual Global Meeting in Seoul, Korea. 

 Ramez Eskander, MD
Clinical Professor Department of Obstetrics, Gynecology, and Reproductive Sciences
University of California San Diego
USA

Eisai have sponsored this initiative with IGCS and had no input into or influence over the content.

Mismatch repair endometrial cancer, what to do at first recurrence and beyond?

Learners will understand the options to treat mismatch repair deficient endometrial cancer and we will discuss what to consider at the time of recurrence in the setting of prior immunotherapy.

Recorded: December 12, 2023
Duration approximately 30 minutes

 Ramez Eskander, MD
Clinical Professor Department of Obstetrics, Gynecology, and Reproductive Sciences
University of California San Diego
USA

Floor Backes, MD
Moderator
Director of Clincial Research and Fellowship Director for the Division of Gynecologic Oncology
The Ohio State University Wexner Medical Center
James Comprehensive Cancer Center
USA

Encouraging Results Seen in Patients with Heavily Pre-Treated Low-Grade Serous Ovarian

WATCH: Dr. Rachel Grisham share results from recent trial and insight from her IGCS 2023 late-breaking abstract EFFICACY AND SAFETY OF AVUTOMETINIB + DEFACTINIB IN RECURRENT LOW-GRADE SEROUS OVARIAN CANCER FOLLOWING PRIOR SYSTEMIC THERAPY

Recorded at IGCS 2023 - November 17, 2023
Duration approximately 20 minutes

Rachel Grisham, MD
Section Head Ovarian Cancer
Director, Gynecologic Medical Oncology
Memorial Sloan Kettering Cancer Center
USA

Wendel Naumann, MD
Moderator
Director of Minimally Invasive Surgery in Gynecologic Oncology
Carolinas Medical Center Associate Medical Director of Clinical Trials
Associate Medical Director of Clinical Trials
Levine Cancer Institute, Atrium Health
USA

Changing the standard of care in 2nd line recurrent cervical cancer

Hear from Dr. Brian Slomovitz as he provides a debrief on the ESMO Congress 20223 LBA innovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer.

Recorded: October 27, 2023
Duration approximately 30 minutes

Brian Slomovitz, MD
Director of Gynecologic Oncologic
Co-Chair of the Cancer Research Committee
Mount Sinai Medical Center
Uterine Cancer Lead for GOG Partner
USA

Floor Backes, MD
Moderator
Director of Clincial Research and Fellowship Director for the Division of Gynecologic Oncology
The Ohio State University Wexner Medical Center
James Comprehensive Cancer Center
USA

Leave a Reply